ReviewDrugs2025
Antibacterials with Novel Chemical Scaffolds in Clinical Development.
Review in Drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- The small molecule regacin binds a conserved pocket in RegA to inhibit the expression of bacterial virulence factors.bioRxiv : the preprint server for biology · 2026Article
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- Article
- Article
- Discovery and Optimization of Novel Nonhydroxamate LpxC Inhibitors for the Treatment of Multidrug-Resistant Gram-Negative Infections.Journal of medicinal chemistry · 2026Article
- The Role of Pyrrolidine in Antibacterial Drug Discovery: Clinically Approved Antibiotics, Novel Derivatives, and Future Perspectives.International journal of molecular sciences · 2026Review
- ECLIPSE: exploring the dark proteome of ESKAPE pathogens through the sequence similarity network of the Protein Universe Atlas.Bioinformatics (Oxford, England) · 2026Article
- Antimicrobial nanomaterials at the nanoscale: design principles, mechanisms, and global challenges.Nanoscale advances · 2026Review
- [Use of vaccines to prevent the development of bacterial resistance].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026Review
- Diversity and antimicrobial products of culturable coral-associated actinomycetes in Hainan.Antonie van Leeuwenhoek · 2026Article
- Synthesis, Antibacterial Activity, and Mechanism of C-6 Aminated β-Carboline Derivatives Against MRSA.Antibiotics (Basel, Switzerland) · 2026Article
- Ultrastructural Study of the Effects of Hybrid Compounds of Natural Monoterpene Carvacrol and Synthetic Cationic Amphiphile DLInternational journal of molecular sciences · 2026Article
- An Imidazo[2,1-b][1,3,4]thiadiazole Derivative Inhibits the Virulence Factor α-Hemolysin by Blocking the Pullout of Its Stem Domain.ChemMedChem · 2026Article
- Mechanistic Insights into the Antimicrobial Effect of Benzodioxane-Benzamides AgainstAntibiotics (Basel, Switzerland) · 2026Article
- Antibacterial Drug Discovery: Deep Learning Successes and Challenges through the Structural Biology Lens.Computational and structural biotechnology journal · 2026Review
- Salmonellosis as a One Health-One Biofilm Challenge: Biofilm Formation byPharmaceuticals (Basel, Switzerland) · 2025Review
- CAUTIon - not all UTIs are the same.Nature reviews. Urology · 2025Review
- The Changing Landscape of Antibiotic Treatment: Reevaluating Treatment Length in the Age of New Agents.Antibiotics (Basel, Switzerland) · 2025Review
- Zosurabalpin: an antibiotic with a new mechanism of action against carbapenem-resistantLe infezioni in medicina · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The rise of antimicrobial resistance represents a significant global health threat, driven by the diminishing efficacy of existing antibiotics, a lack of novel antibacterials entering the market, and an over- or misuse of existing antibiotics, which accelerates the evolution of resistant bacterial strains. This review focuses on innovative therapies by highlighting 19 novel antibacterials in clinical development as of June 2024. These selected compounds are characterized by new chemical scaffolds, novel molecular targets, and/or unique mechanisms of action, which render their potential to break antimicrobial resistance particularly high. A detailed analysis of the scientific foundations behind each of these compounds is provided, including their pharmacodynamic profiles, current development state, and potential for overcoming existing limitations in antibiotic therapy. By presenting this subset of chemically novel antibacterials, the review highlights the ability to innovate in antibiotic drug development to counteract bacterial resistance and improve treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.